• Users Online: 94
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2014| September-December  | Volume 7 | Issue 3  
    Online since April 19, 2018

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
REVIEW FOR THE SHEIKH HAMDAN BIN RASHID AL MAKTOUM AWARD FOR MEDICAL SCIENCES
Drugging the cancer genome – discovery of small-molecule targeted therapeutics for personalized, precision medicine
Paul Workman
September-December 2014, 7(3):289-303
DOI:10.7707/hmj.344  
[ABSTRACT]   Full text not available  [PDF] [CITATIONS]
  1 546 74
Antiproliferative and pro-apoptotic actions of oestrogen receptor β in prostate cancer
Jan-Ake Gustafsson, Anders Ström
September-December 2014, 7(3):403-409
DOI:10.7707/hmj.354  
[ABSTRACT]   Full text not available  [PDF] [CITATIONS]
  1 485 82
BOOK REVIEW
With Head, Heart and Hands, Make a Medical Professional by Abdul Jabbar Mehdi Salih
Harald Rosen
September-December 2014, 7(3):275-275
DOI:10.7707/hmj.379  
Full text not available  [PDF]
  - 282 93
REVIEW FOR THE SHEIKH HAMDAN BIN RASHID AL MAKTOUM AWARD FOR MEDICAL SCIENCES
Imatinib (Glivec®) as a paradigm of targeted cancer therapies
Brian J Druker
September-December 2014, 7(3):277-287
DOI:10.7707/hmj.343  
[ABSTRACT]   Full text not available  [PDF]
  - 523 83
Rotarix™ from early discovery to widespread use
Richard L Ward, David I Bernstein
September-December 2014, 7(3):411-420
DOI:10.7707/hmj.356  
[ABSTRACT]   Full text not available  [PDF]
  - 434 54
The golden anniversary of the measles vaccine
Samuel L Katz
September-December 2014, 7(3):421-424
DOI:10.7707/hmj.357  
[ABSTRACT]   Full text not available  [PDF]
  - 468 49
Repurposing failed pharmaceuticals as the first targeted medicines for the treatment and prevention of breast cancer
V Craig Jordan
September-December 2014, 7(3):305-315
DOI:10.7707/hmj.345  
[ABSTRACT]   Full text not available  [PDF]
  - 479 51
Discovery of first-in-class therapeutics – venlafaxine (Effexor®), desvenlafaxine (Pristiq®), temsirolimus (Toresil®), ILS-920 and gemtuzumab ozogamicin (Mylotarg®)
Magid Abou-Gharbia
September-December 2014, 7(3):317-331
DOI:10.7707/hmj.346  
[ABSTRACT]   Full text not available  [PDF]
  - 677 115
Haematopoietic cell transplantation – from its birth to the twenty-first century
Rainer Storb
September-December 2014, 7(3):333-341
DOI:10.7707/hmj.347  
[ABSTRACT]   Full text not available  [PDF]
  - 459 71
Progress in vaccination
Stanley A Plotkin
September-December 2014, 7(3):343-353
DOI:10.7707/hmj.348  
[ABSTRACT]   Full text not available  [PDF]
  - 525 56
Cell therapy for cancer – our synthetic future
Carl H June
September-December 2014, 7(3):355-365
DOI:10.7707/hmj.349  
[ABSTRACT]   Full text not available  [PDF]
  - 435 47
The evolution of targeted therapy of the erbB2/neu oncoprotein for human cancer therapy
E Aaron Runkle, Mark I Greene
September-December 2014, 7(3):367-373
DOI:10.7707/hmj.351  
[ABSTRACT]   Full text not available  [PDF]
  - 429 49
Graft-versus-host disease, a major complication after stem cell transplantation – home care for prevention and stromal cells for therapy
Olle Ringden
September-December 2014, 7(3):375-387
DOI:10.7707/hmj.352  
[ABSTRACT]   Full text not available  [PDF]
  - 454 69
Inhibitors of the ‘point of no return’ in human immunodeficiency virus infectivity – discovery of novel antihuman immunodeficiency virus integrase compounds with dual mechanism of action
Vasu Nair, Maurice O Okello
September-December 2014, 7(3):389-402
DOI:10.7707/hmj.353  
[ABSTRACT]   Full text not available  [PDF]
  - 481 61